Evolving Roles of SGLT2 Inhibitors in Cats (And Dogs??) With Diabetes

Saturday, January 17, 2026 3:05 PM to 3:55 PM · 50 min. (America/New_York)

S310 A

Endocrinology

Information

Discover how SGLT2i are changing the management of diabetes in cats and dogs. This session will explore real world clinical experience, emerging roles and future directions for integrating SGLT2 inhibitors into small animal practice.

VMX Virtual Availability

This session is available On-Demand as part of the VMX Virtual Event

Program

Elanco Internal Medicine/Specialty Symposium

CE Credit

Primary Discipline

Small Animal

Secondary Discipline

Feline

Learning Level

Intermediate

One Day Access

Saturday

Manuscript

Manuscript NOT Available

RACE Credit Type

Medical

Elanco4617Elanco Animal Health is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities.

Speaker

Jocelyn Mott

University of FloridaUniversity of Florida

Registered attendees

Brittany Aguilar

Scientific Communications VeterinarianRoyal Canin

Chris George

Medical Affairs Specialist - Internal Medicine/Infectious DiseaseElanco Animal Health

GC Ritchie

veterinarianRitchie Consulting LLC

Evolving Roles of SGLT2 Inhibitors in Cats (And Dogs??) With Diabetes

Information

Speaker

Registered attendees

Join the event!

Log in